Progress and challenges in developing aptamer-functionalized targeted drug delivery systems

International Journal of Molecular Sciences

Volumn 16, Issue 10, 2015, Pages 23784-23822

  Jiang, Feng ^a   Liu, Biao ^a   Lu, Jun ^a   Li, Fangfei ^a   Li, Defang ^a   Liang, Chao ^a   Dang, Lei ^a   Liu, Jin ^a   He, Bing ^a   Badshah, Shaikh Atik ^a   Lu, Cheng ^a   He, Xiaojuan ^a   Guo, Baosheng ^a   Zhang, Xiao Bing ^b   Tan, Weihong ^b   Lu, Aiping ^a   Zhang, Ge ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b HUNAN UNIVERSITY   (China)

Author keywords

Aptamer; Aptamer functionalized targeted drug delivery systems; Aptamer nanomaterial conjugated systems; Aptamer small molecule conjugated systems; SELEX

Indexed keywords

ACID CLEAVABLE LINKER; ANTINEOPLASTIC AGENT; APTAMER; AS1411; BAY 94 9343; BETA GLUCURONIDE LINKER; BIOLOGICAL MARKER; BT 062; COLTUXIMAB RAVTANSINE; CYTOTOXIC AGENT; DISULFIDE LINKER; DOXORUBICIN; EGAPTIVON PEGOL; GEMTUZUMAB OZOGAMICIN; IMGN529; LIGAND; LINKER; LORVOTUZUMAB MERTANSINE; MILATUZUMAB; NON CLEAVABLE LINKER; PEGAPTANIB; PEPTIDE LINKER; PREDNISOLONE TEBUTATE; SAR 566658; SGC8; TD05; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOTIN; NANOMATERIAL;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CLINICAL TRIAL (TOPIC); COMBINATORIAL CHEMISTRY; DNA SEQUENCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RELEASE; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; HUMAN; IC50; MOLECULAR RECOGNITION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY; ANIMAL; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

ANIMALS; APTAMERS, NUCLEOTIDE; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; NANOSTRUCTURES; SELEX APTAMER TECHNIQUE;

EID: 84944056206     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161023784     Document Type: Review

References (163)

1. Dosio, F.; Brusa, P.; Cattel, L. Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components. Toxins 2011, 3, 848–883.
2. Muro, S. Challenges in design and characterization of ligand-targeted drug delivery systems. J. Control. Release 2012, 164, 125–137.
3. Kamaly, N.; Xiao, Z.; Valencia, P.M.; Radovic-Moreno, A.F.; Farokhzad, O.C. Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem. Soc. Rev. 2012, 41, 2971–3010.
4. Jaracz, S.; Chen, J.; Kuznetsova, L.V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13, 5043–5054.
5. Jin, E.L.; Zhang, B.; Sun, X.R.; Zhou, Z.X.; Ma, X.P.; Sun, Q.H.; Tang, J.B.; Shen, Y.Q.; Kirk, E.V.; Murdoch, W.J. et al. Acid active cell-penetrating peptides for in vivo tumor-targeted drug delivery. J. Am. Chem. Soc. 2013, 135, 933–940.
6. Jarosch, F.; Buchner, K.; Klussmann, S. In vitro selection using a dual RNA library that allows primerless selection. Nucleic Acids Res. 2006, 34, e86, doi:10.1093/nar/gkl463.
7. Kong, H.Y.; Byun, J. Nucleic acid aptamers: New methods for selection, stabilization, and application in biomedical science. Biomol. Ther. 2013, 21, 423–434.
8. Liang, H.; Zhang, X.B.; Lv, Y.; Gong, L.; Wang, R.; Zhu, X.; Yang, R.; Tan, W. Functional DNA-containing nanomaterials: Cellular applications in biosensing, imaging, and targeted therapy. Acc. Chem. Res. 2014, 47, 1891–1901.
9. Li, X.; Zhao, Q.; Qiu, L. Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. J. Control. Release 2013, 171, 152–162.
10. Mosing, R.K.; Bowser, M.T. Isolating aptamers using capillary electrophoresis-SELEX (CE-SELEX). Methods Mol. Biol. 2009, 535, 33–43.
11. Glökler, J.; Schütze, T.; Konthur, Z. Automation in the high-throughput selection of random combinatorial libraries—different approaches for select applications. Molecules 2010, 15, 2478–2490.
12. Blind, M.; Blank, M. Aptamer selection technology and recent advances. Mol. Ther. Nucleic Acids 2015, 4, e223, doi:10.1038/mtna.2014.74.
13. Elle, I.C.; Karlsen, K.K.; Terp, M.G.; Larsen, N.; Nielsen, R.; Derbyshire, N.; Mandrup, S.; Ditzel, H.J.; Wengel, J. Selection of LNA-containing DNA aptamers against recombinant human CD73. Mol. Biosyst. 2015, 11, 1260–1270.
14. Murgha, Y.E.; Rouillard, J.M.; Gulari, E. Methods for the preparation of large quantities of complex single-stranded oligonucleotide libraries. PLoS ONE 2014, 9, e94752.
15. Yang, J.; Bowser, M.T. Capillary electrophoresis-SELEX selection of catalytic DNA aptamers for a small-molecule porphyrin target. Anal. Chem. 2013, 85, 1525–1530.
16. Yang, Y.; Yang, D.; Schluesener, H.J.; Zhang, Z. Advances in SELEX and application of aptamers in the central nervous system. Biomol. Eng. 2007, 24, 583–592.
17. Tok, J.; Lai, J.; Leung, T.; Li, S.F. Selection of aptamers for signal transduction proteins by capillary electrophoresis. Electrophoresis 2010, 31, 2055–2062.
18. Bruno, J.G.; Phillips, T.; Montez, T.; Garcia, A.; Sivils, J.C.; Mayo, M.W.; Greis, A. Development of a fluorescent enzyme-linked DNA aptamer-magnetic bead sandwich assay and portable fluorometer for sensitive and rapid listeria detection. J. Fluoresc. 2015, 25, 173–183.
19. Stoltenburg, R.; Reinemann, C.; Strehlitz, B. FluMag-SELEX as an advantageous method for DNA aptamer selection. Anal. Bioanal. Chem. 2005, 383, 83–91.
20. Liang, C.; Li, D.; Zhang, G.; Li, H.; Shao, N.; Liang, Z.; Zhang, L.; Lu, A.; Zhang, G. Comparison of the methods for generating single-stranded DNA in SELEX. Analyst 2015, 140, 3439–3444.
21. Zhou, J.; Rossi, J.J. Cell-type-specific, aptamer-functionalized agents for targeted disease. Mol. Ther. Nucleic Acids 2014, 3, doi:10.1038/mtna.2014.21.
22. Chen, W.X.; Zhang, K.H.; Zou, X.S.; Chen, Y.Q.; Li, J.G. Screening and identification of the nucleic acid aptamers in nasopharyngeal carcinoma. Genet. Mol. Res. 2013, 12, 6850–6857.
23. Dickinson, H.; Lukasser, M.; Mayer, G.; Hüttenhofer, A. Cell-SELEX: In vitro selection of synthetic small specific ligands. Methods Mol. Biol. 2015, 1296, 213–224.
24. Zhu, H.; Li, J.; Zhang, X.B.; Ye, M.; Tan, W. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy. ChemMedChem 2015, 10, 39–45.
25. Kim, J.W.; Kim, E.Y.; Kim, S.Y.; Byun, S.K.; Lee, D.; Oh, K.J.; Kim, W.K.; Han, B.S.; Chi, S.W.; Lee, S.C. et al. Identification of DNA aptamers toward epithelial cell adhesion molecule via cell-SELEX. Mol. Cells 2014, 37, 742–746.
26. Liang, C.; Guo, B.; Wu, H.; Shao, N.; Li, D.; Liu, J.; Dang, L.; Wang, C.; Li, H.; Li, S. et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat. Med. 2015, 21, 288–294.
27. Conidi, A.; van den Berghe, V.; Huylebroeck, D. Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling. Int. J. Mol. Sci. 2013, 14, 6690–6719.
28. Hoinka, J.; Zotenko, E.; Friedman, A.; Sauna, Z.E.; Przytycka, T.M. Identification of sequence-structure RNA binding motifs for SELEX-derived aptamers. Bioinformatics 2012, 28, i215–i223.
29. Stoltenburg, R.; Reinemann, C.; Strehlitz, B. SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 2007, 24, 381–403.
30. Cox, J.C.; Ellington, A.D. Automated selection of anti-protein aptamers. Bioorg. Med. Chem. 2001, 9, 2525–2531.
31. Eulberg, D.; Buchner, K.; Maasch, C.; Klussmann, S. Development of an automated in vitro selection protocol to obtain RNA-based aptamers: Identification of a biostable substance P antagonist. Nucleic Acids Res. 2005, 33, e45, doi:10.1093/nar/gni044.
32. Fang, X.; Tan, W. Aptamers generated from cell-SELEX for molecular medicine: A chemical biology approach. Acc. Chem. Res. 2010, 43, 48–57.
33. Seo, Y.J.; Chen, S.; Nilsen-Hamilton, M.; Levine, H.A. A mathematical analysis of multiple-target SELEX. Bull. Math. Biol. 2010, 72, 1623–1665.
34. Morris, K.N.; Jensen, K.B.; Julin, C.M.; Weil, M.; Larry, G. High affinity ligands from in vitro selection: Complex targets. Proc. Natl. Acad. Sci. USA 1998, 95, 2902–2907.
35. Shamah, S.M.; Healy, J.M.; Cload, S.T. Complex target SELEX. Acc. Chem. Res. 2008, 41, 130–138.
36. Sun, H.; Zhu, X.; Lu, P.Y.; Rosato, R.R.; Tan, W.; Zu, Y. Oligonucleotide aptamers: New tools for targeted cancer therapy. Mol. Ther. Nucleic Acids 2014, 3, doi:10.1038/mtna.2014.32.
37. Gragoudas, E.S.; Adamis, A.P.; Cunningham, E.T.; Feinsod, M.; Guyer, D.R. Pegaptanib for Neovascular Age-Related Macular Degeneration. N. Engl. J. Med. 2004, 351, 2805–2816.
38. Bates, P.J.; Laber, D.A.; Miller, D.M.; Thomas, S.D.; Trent, J.O. Discovery and Development of the G-rich Oligonucleotide AS1411 as a Novel Treatment for Cancer. Exp. Mol. Pathol. 2009, 86, 151–164.
39. Shangguan, D.; Cao, Z.; Meng, L.; Mallikaratchy, P.; Sefah, K.; Wang, H.; Li, Y.; Tan, W. Cell-Specific Aptamer Probes for Membrane Protein Elucidation in Cancer Cells. J. Prot. Res. 2008, 7, 2133–2139.
40. Mallikaratchy, P.; Tang, Z.; Kwame, S.; Meng, L.; Shangguan, D.; Tan, W. Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt’s Lymphoma Cells. Mol. Cell. Proteom. 2007, 6, 2230–2238.
41. Tope, S.; Maske, S.; Nagulwar, V.; Sufi, J.; Welankiwar, A. Aptamers as therapeutics. Indo Am. J. Pharm. Res. 2013, 3, 2718–2743.
42. Bock, L.C.; Griffin, L.C.; Latham, J.A.; Vermaas, E.H.; Toole, J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992, 355, 564–566.
43. Tan, W.; Wang, H.; Chen, Y.; Zhang, X.; Zhu, H.; Yang, C.; Yang, R.; Liu, C. Molecular aptamers for drug delivery. Trends Biotechnol. 2011, 29, 634–640.
44. Famulok, M.; Hartig, J.S.; Mayer, G. Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy. Chem. Rev. 2007, 107, 3715–3743.
45. Gold, L.; Polisky, B.; Uhlenbeck, O.; Yarus, M. Diversity of Oligonucleotide Functions. Annu. Rev. Biochem. 1995, 64, 763–767.
46. Burmeister, P.E.; Lewis, S.D.; Silva, R.F.; Preiss, J.R.; Horwitz, L.R.; Pendergrast, P.S.; McCauley, T.G.; Kurz, J.C.; Epstein, D.M.; Wilson, C. et al. Direct in Vitro Selection of a 2′-O-Methyl Aptamer to VEGF. Chem. Biol. 2005, 12, 25–33.
47. Bates, P.J.; Kahlon, J.B.; Thomas, S.D.; Trent, J.O.; Miller, D.M. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem. 1999, 274, 26369–26377.
48. Dapić, V.; Abdomerović, V.; Marrington, R.; Peberdy, J.; Rodger, A.; Trent, J.O.; Bates, P.J. Biophysical and biological properties of quadruplex oligodeoxyribonucle otides. Nucleic Acids Res. 2003, 31, 2097–2107.
49. Dapić, V.; Bates, P.J.; Trent, J.O.; Rodger, A.; Thomas, S.D.; Miller, D.M. Antiproliferative activity of G-quartetforming oligonucleotides with backbone and sugar modifications. Biochemistry 2002, 41, 3676–3685.
50. Reyes-Reyes, E.M.; Teng, Y.; Bates, P.J. A new paradigm for aptamer therapeutic AS1411 action: Uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010, 70, 8617–8629.
51. Huang, Y.F.; Shangguan, D.; Liu, H.; Phillips, J.A.; Zhang, X.; Chen, Y.; Tan, W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 2009, 10, 862–868.
52. Wang, R.W.; Zhu, G.; Mei, L.; Xie, Y.; Ma, H.; Ye, M.; Qing, F.L.; Tan, W. Automated modular synthesis of aptamer-drug conjugates for targeted drug delivery. J. Am. Chem. Soc. 2014, 136, 2731–2734.
53. Senter, P.D. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 2009, 13, 235–244.
54. Teicher, B.A.; Chari, R.V.J. Antibody conjugate therapeutics: Challenges and potential. Clin. Cancer Res. 2011, 17, 6389–6397.
55. Lee, M.D.; Dunne, T.S.; Siegel, M.M.; Chang, C.C.; Morton, G.O.; Borders, D.B. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin γ1. J. Am. Chem. Soc. 1987, 109, 3464–3466.
56. Kupchan, S.M.; Komoda, Y.; Court, W.A.; Thomas, G.J.; Smith, R.M.; Karim, A.; Gilmore, C.J.; Haltiwanger, R.C.; Bryan, R.F. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J. Am. Chem. Soc. 1972, 94, 1354–1356.
57. Pettit, G.R.; Kamano, Y.; Herald, C.L.; Tuinman, A.A.; Boettner, F.E.; Kizu, H.; Schmidt, J.M.; Baczynskyj, L.; Tomer, K.B.; Bontems, R.J. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J. Am. Chem. Soc. 1987, 109, 6883–6885.
58. Bai, R.; Petit, G.R.; Hame, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 1990, 39, 1941–1949.
59. Hartley, J.A.; Hamaguchi, A.; Suggitt, M.; Gregson, S.J.; Thurston, D.E.; Howard, P.W. DNA inter strand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057. Investig. New Drugs 2012, 30, 950–958.
60. Hartley, J.A. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin. Investig. Drugs 2011, 20, 733–744.
61. Moldenhauer, G.; Salnikov, A.V.; Luttgau, S.; Herr, I.; Anderl, J.; Faulstich, H. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesionmolecule monoclonal antibody against pancreatic carcinoma. J. Natl. Cancer Inst. 2012, 104, 622–634.
62. Chari, R.V.J. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc. Chem. Res. 2008, 41, 98–107.
63. Kemshead, J.T.; Hopkins, K. Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: A review. J. R. Soc. Med. 1993, 86, 219–224.
64. Trail, P.A.; Willner, D.; Lasch, S.J.; Henderson, A.J.; Hofstead, S.; Casazza, A.M.; Firestone, R.A.; Hellstrom, K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261, 212–215.
65. Casi, G.; Neri, D. Antibody-drug conjugates: Basic concepts, examples and future perspectives. J. Control. Release 2012, 161, 422–428.
66. DiJoseph, J.F.; Dougher, M.M.; Kalyandrug, L.B.; Armellino, D.C.; Boghaert, E.R.; Hamann, P.R.; Moran, J.K.; Damle, N.K. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin. Cancer Res. 2006, 12, 242–249.
67. De Groot, F.M.; Damen, E.W.; Scheeren, H.W. Anticancer prodrugs for application in monotherapy: Targeting hypoxia, tumor-associated enzymes, and receptors. Curr. Med. Chem. 2001, 8, 1093–1122.
68. Singh, Y.; Palombo, M.; Sinko, P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem. 2008, 15, 1802–1826.
69. Ranson, M.; Sliwkowski, M.X. Perspectives on anti-HER monoclonal antibodies. Oncology 2002, 63, 17–24.
70. Erickson, H.K.; Widdison, W.C.; Mayo, M.F.; Whiteman, K.; Audette, C.; Wilhelm, S.D.; Singh, R. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug. Chem. 2010, 21, 84–92.
71. Erickson, H.K.; Park, P.U.; Widdison, W.C.; Kovtun, Y.V.; Garrett, L.M.; Hoffman, K.; Lutz, R.J.; Goldmacher, V.S.; Blättler, W.A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006, 66, 4426–4433.
72. Kovtun, Y.V.; Audette, C.A.; Ye, Y.; Xie, H.; Ruberti, M.F.; Phinney, S.J.; Leece, B.A.; Chittenden, T.; Blättler, W.A.; Goldmacher, V.S. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006, 66, 3214–3221.
73. Xie, H.; Audette, C.; Hoffee, M.; Lambert, J.M.; Blättler, W.A. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 2004, 308, 1073–1082.
74. Sanderson, R.J.; Hering, M.A.; James, S.F.; Sun, M.M. C.; Doronina, S.O.; Siadak, A.W.; Senter, P.D.; Wahl, A.F. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 2005, 11, 843–852.
75. Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.; DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21, 778–784.
76. Francisco, J.A.; Cerveny, C.G.; Meyer, D.L.; Mixan, B.J.; Klussman, K.; Chace, D.F.; Rejniak, S.X.; Gordon, K.A.; DeBlanc, R.; Toki, B.E. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102, 1458–1465.
77. Jeffrey, S.C.; Andreyka, J.B.; Bernhardt, S.X.; Kissler, K.M.; Kline, T.; Lenox, J.S.; Moser, R.F.; Nguyen, M.T.; Okeley, N.M.; Stone, I.J. et al. Development and properties of β-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug. Chem. 2006, 17, 831–840.
78. De Graaf, M.; Boven, E.; Scheeren, H.W.; Haisma, H.J.; Pinedo, H.M. Beta-glucuronidase-mediated drug release. Curr. Pharm. Des. 2002, 8, 1391–1403.
79. Jeffrey, S.C.; Nguyen, M.T.; Moser, R.F.; Meyer, D.L.; Miyamoto, J.B.; Senter, P.D. Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker. Bioorg. Med. Chem. Lett. 2007, 17, 2278–2280.
80. Burke, P.J.; Senter, P.D.; Meyer, D.W.; Miyamoto, J.B.; Anderson, M.; Toki, B.E.; Manikumar, G.; Wani, M.C.; Kroll, D.J.; Jeffrey, S.C. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Bioconjug. Chem. 2009, 20, 1242–1250.
81. Alley, S.C.; Benjamin, D.R.; Jeffrey, S.C.; Okeley, N.M.; Meyer, D.L.; Sanderson, R.J.; Senter, P.D. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 2008, 19, 759–765.
82. Doronina, S.O.; Mendelsohn, B.A.; Bovee, T.D.; Cerveny, C.G.; Alley, S.C.; Meyer, D.L.; Oflazoglu, E.; Toki, B.E.; Sanderson, R.J.; Zabinski, R.F. et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 2006, 17, 114–124.
83. Phillips, G.D.L.L.; Blättler, W.A.; Lambert, J.M.; Chari, R.V.J.; Lutz, R.J.; Wong, W.L.T.; Jacobson, F.S.; Koeppen, H.; Schwall, R.H.; Kenkare-Mitra, S.R. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68, 9280–9290.
84. Cohen, R.; Vugts, D.J.; Visser, G.W.; Stigter-van, W.M.; Bolijn, M.; Spiga, M.; Lazzari, P.; Shankar, S.; Sani, M.; Zanda, M. et al. Development of novel ADCs: Conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. Cancer Res. 2014, 74, 5700–5710.
85. Pillow, T.H.; Tien, J.; Parsons-Reponte, K.L.; Bhakta, S.; Li, H.; Staben, L.R.; Li, G.; Chuh, J.; Fourie-O Donohue, A.; Darwish, M. et al. Site-specific trastuzumab maytansinoid antibody−drug conjugates with improved therapeutic activity through linker and antibody engineering. J. Med. Chem. 2014, 57, 7890–7899.
86. Drake, P.M.; Albers, A.E.; Baker, J.; Banas, S.; Barfield, R.M.; Bhat, A.S.; de Hart, G.W.; Garofalo, A.W.; Holder, P.; Jones, L.C. et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug. Chem. 2014, 25, 1331–1341.
87. Kolodych, S.; Koniev, O.; Baatarkhuu, Z.; Bonnefoy, J.Y.; Debaene, F.; Cianférani, S.; Dorsselaer, A.V.; Wagner, A. CBTF: New amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability. Bioconjug. Chem. 2015, 26, 197–200.
88. Zhao, N.; Pei, S.-N.; Qi, J.; Zeng, Z.; Iyer, S.P.; Lin, P.; Tung, C.-H.; Zu, Y. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials 2015, 67, 42–51.
89. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 2008, 26, 57–64.
90. Vigderman, L.; Zubarev, E.R. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv. Drug Deliv. Rev. 2013, 65, 663–676.
91. Subinoy, R.; Avinash, B.; Rubul, M.; Vincent, M.R. Monolayer coated gold nanoparticles for delivery applications. Adv. Drug Deliv. Rev. 2012, 64, 200–216.
92. Luo, Y.L.; Shiao, Y.S.; Huang, Y.F. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy. ACS Nano 2011, 5, 7796–7804.
93. Yang, X.; Liu, X.; Liu, Z.; Pu, F.; Ren, J.; Qu, X. Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles. Adv. Mater. 2012, 24, 2890–2895.
94. Wang, J.; Zhu, G.; You, M.; Song, E.; Shukoor, M.I.; Zhang, K.; Altman, M.B.; Chen, Y.; Zhu, Z.; Huang, C.Z. et al. Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy. ACS Nano 2012, 6, 5070–5077.
95. Wang, J.; Sefah, K.; Altman, M.B.; Chen, T.; You, M.; Zhao, Z.; Huang, C.Z.; Tan, W. Aptamer-conjugated nanorods for targeted photothermal therapy of prostate cancer stem cells. Chem. Asian J. 2013, 8, 2417–2422.
96. Dreaden, E.C.; Austin, L.A.; Mackey, M.A.; El-Sayed, M.A. Size matters: Gold nanoparticles in targeted cancer drug delivery. Ther. Deliv. 2012, 3, 457–478.
97. Mohapatra, M.; Anand, S. Synthesis and applications of nano-structured iron oxides/hydroxides—A review. Int. J. Eng. Sci. Technol. 2010, 2, 127–146.
98. Chen, T.; Shukoor, M.I.; Wang, R.; Zhao, Z.; Yuan, Q.; Bamrungsap, S.; Xiong, X.; Wei, T. Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging. ACS Nano 2011, 5, 7866–7873.
99. Zhang, L.; Dong, W.F.; Sun, H.B. Multifunctional superparamagnetic iron oxide nanoparticles: Design, synthesis and biomedical photonic applications. Nanoscale 2013, 5, 7664–7684.
100. Mahmoudi, M.; Sant, S.; Wang, B.; Laurent, S.; Sen, T. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Adv. Drug Deliv. Rev. 2011, 63, 24–46.
101. Wang, Y.X.; Hussain, S.M.; Krestin, G.P. Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur. Radiol. 2001, 11, 2319–2331.
102. Weissleder, R.; Elizondo, G.; Wittenberg, J.; Rabito, C.A.; Bengele, H.H.; Josephson, L. Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging. Radiology 1990, 175, 489–493.
103. Leenders, W. Ferumoxtran-10 advanced magnetics. IDrugs 2003, 6, 987–993.
104. Wang, A.Z.; Bagalkot, V.; Vasilliou, C.C.; Gu, F.; Alexis, F.; Zhang, L.; Shaikh, M.; Yuet, K.; Cima, M.J.; Langer, R. et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3, 1311–1315.
105. Yu, M.K.; Kim, D.; Lee, I.H.; So, J.S.; Jeong, Y.Y.; Jon, S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 2011, 7, 2241–2249.
106. Laurent, S.; Saei, A.A.; Behzadi, S.; Panahifar, A.; Mahmoudi, M. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: Opportunities and challenges. Expert Opin. Drug Deliv. 2014, 11, 1449–1470.
107. Wahajuddin A; Arora, S. Superparamagnetic iron oxide nanoparticles: Magnetic nanoplatforms as drug carriers. Int. J. Nanomed. 2012, 7, 3445–3471.
108. Meng, L.; Zhang, X.; Lu, Q.; Fei, Z.; Dyson, P.J. Single walled carbon nanotubes as drug delivery vehicles: Targeting DOXorubicin to tumors. Biomaterials 2012, 33, 1689–1698.
109. Zhu, Z.; Tang, Z.; Phillips, J.A.; Yang, R.; Wang, H.; Tan, W. Regulation of singlet oxygen generation using single-walled carbon nanotubes. J. Am. Chem. Soc. 2008, 130, 10856–10857.
110. Zhang, H.; Hou, L.; Jiao, X.; Ji, Y.; Zhu, X.; Li, H.; Chen, X.; Ren, J.; Xia, Y.; Zhang, Z. In vitro and in vivo evaluation of antitumor drug-loaded aptamer targeted single-walled carbon nanotubes system. Curr. Pharm. Biotechnol. 2014, 14, 1105–1117.
111. Lu, Y.; Wu, P.; Yin, Y.; Zhang, H.; Cai, C. Aptamer-functionalized graphene oxide for highly efficient loading and cancer cell-specific delivery of antitumor drug. J. Mater. Chem. B 2014, 2, 3849–3859.
112. Rodriguesand, D.; Elimelech, M. Toxic effects of single-walled carbon nanotubes in the development of E. coli biofilm. Environ. Sci. Technol. 2010, 44, 4583–4589.
113. Chen, Y.-C.; Huang, X.-C.; Luo, Y.-L.; Chang, Y.-C.; Hsieh, Y.-Z.; Hsu, H.-Y. Non-metallic nanomaterials in cancer theranostics: A review of silica- and carbon-based drug delivery systems. Sci. Technol. Adv. Mater. 2013, 14, 044407, doi:10.1088/1468-6996/14/4/044407.
114. Slowing, I.I.; Vivero-Escoto, J.L.; Wu, C.W.; Lin, V.S.Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 2008, 60, 1278–1288.
115. Zhu, C.L.; Song, X.Y.; Zhou, W.H.; Yang, H.H.; Wen, Y.H.; Wang, X.R. An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates. J. Mater. Chem. 2009, 19, 7765–7770.
116. Li, L.L.; Yin, Q.; Cheng, J.; Lu, Y. Polyvalent Mesoporous Silica Nanoparticle-Aptamer Bioconjugates Target Breast Cancer Cells. Adv. Healthc. Mater. 2012, 1, 567–572.
117. Chen, Y.; Chen, H.; Shi, J. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv. Mater. 2013, 25, 3144–3176.
118. Dey, N.S.; Rao, M.E.B. Quantum dot: Novel carrier for drug delivery. Int. J. Res. Pharm. Biomed. Sci. 2011, 2, 448–458.
119. Qi, L.; Gao, X. Emerging application of quantum dots for drug delivery and therapy. Expert Opin. Drug Deliv. 2008, 5, 263–267.
120. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P.W.; Langer, R.; Farokhzad, O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007, 7, 3065–3070.
121. Savla, R.; Taratula, O.; Garbuzenko, O.; Minko, T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control. Release 2011, 153, 16–22.
122. Winnik, F.M.; Maysinger, D. Quantum dot cytotoxicity and ways to reduce it. Acc. Chem. Res. 2013, 46, 672–680.
123. Ghaderi, S.; Ramesh, B.; Seifalian, A.M. Fluorescence nanoparticles “quantum dots” as drug delivery system and their toxicity: A review. J. Drug Target. 2011, 19, 475–486.
124. Hardman, R. A toxicologic review of quantum dots: Toxicity depends on physicochemical and environmental factors. Environ. Health Perspect. 2006, 114, 165–172.
125. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and Applications. Nanoscale Res. Lett. 2013, 8, 102–110.
126. Wagner, A.; Platzgummer, M.; Kreismayr, G.; Quendler, H.; Stiegler, G.; Ferko, B.; Vecera, G.; Vorauer-Uhl, K.; Katinger, H. GMP production of liposomes—a new industrial approach. J. Liposome Res. 2006, 16, 311–319.
127. Kaneda, Y. Virosomes: Evolution of the liposome as a targeted drug delivery system. Adv. Drug Deliv. Rev. 2000, 43, 197–205.
128. Cao, Z.; Tong, R.; Mishra, A.; Xu, W.; Wong, G.C.; Cheng, J.; Lu, Y. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew. Chem. Int. Ed. 2009, 48, 6494–6498.
129. Kang, H.; O’Donoghue, M.B.; Liu, H.; Tan, W. A liposome-based nanostructure for aptamer directed delivery. Chem. Commun. 2010, 46, 249–251.
130. Xing, H.; Tang, L.; Yang, X.; Hwang, K.; Wang, W.; Yin, Q.; Wong, N.Y.; Dobrucki, L.W.; Yasui, N.; Katzenellenbogen, J.A. et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J. Mater. Chem. B 2013, 1, 5288–5297.
131. Baek, S.E.; Lee, K.H.; Park, Y.S.; Oh, D.K.; Oh, S.; Kim, K.S.; Kim, D.E. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. J. Control. Release 2014, 196, 234–242.
132. Alshaer, W.; Hillaireau, H.; Vergnaud, J.; Ismail, S.; Fattal, E. Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells. Bioconjug. Chem. 2015, 26, 1307–1313.
133. Langer, R. Drug delivery and targeting. Nature 1998, 392, 5–10.
134. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5, 505–515.
135. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymer nanospheres. Science 1994, 263, 1600–1603.
136. Farokhzad, O.C.; Cheng, J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006, 103, 6315–6320.
137. Dhar, S.; Gu, F.X.; Langer, R.; Farokhzad, O.C.; Lippard, S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. USA 2008, 105, 17356–17361.
138. Dhar, S.; Kolishettib, N.; Lipparda, S.J.; Farokhzad, O.C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. USA 2011, 108, 1850–1855.
139. Gu, F.; Zhang, L.F.; Teply, B.A.; Mann, N.; Wang, A.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. USA 2008, 105, 2586–2591.
140. Huang, F.; You, M.; Chen, T.; Zhu, G.; Liang, H.; Tan, W. Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells. Chem. Commun. 2014, 50, 3103–3105.
141. Kedar, U.; Phutane, P.; Shidhaye, S.; Kadam, V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6, 714–729.
142. Wu, Y.R.; Sefah, K.; Liu, H.P.; Wang, R.W.; Tan, W.H. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Natl. Acad. Sci. USA 2010, 107, 5–10.
143. Mu, C.; Dave, N.; Hu, J.; Desai, P.; Pauletti, G.; Bai, S.; Hao, J. Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro. J. Microencapsul. 2013, 30, 701–708.
144. Xu, W.; Siddiqui, I.A.; Nihal, M.; Pilla, S.; Rosenthal, K.; Mukhtar, H.; Gong, S. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 2013, 34, 5244–5253.
145. Li, X.; Yu, Y.; Ji, Q.; Qiu, L. Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles. Nanomedicine 2015, 11, 175–184.
146. Zhang, J.; Chen, R.; Fang, X.; Chen, F.; Wang, Y.; Chen, M. Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel. Nano Res. 2015, 8, 201–218.
147. Deng, C.; Jiang, Y.; Cheng, R.; Meng, F.; Zhong, Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, progress and prospects. Nano Today 2012, 7, 467–480.
148. Tripathy, S.; Das, M.K. Dendrimers and their applications as novel drug delivery carriers. J. Appl. Pharm. Sci. 2013, 3, 142–149.
149. Nanjwadea, B.K.; Bechra, H.M.; Derkar, G.K.; Manvi, F.V.; Nanjwade, V.K. Dendrimers: Emerging polymers for drug-delivery systems. Eur. J. Pharm. Sci. 2009, 38, 185–196.
150. Pednekar, P.P.; Jadhav, K.R.; Kadam, V.J. Aptamer-dendrimer bioconjugate: A nanotool for therapeutics, diagnosis, and imaging. Expert Opin. Drug Deliv. 2012, 9, 1273–1288.
151. Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148, 135–146.
152. Lee, I.H.; An, S.; Yu, M.K.; Kwon, H.K.; Im, S.H.; Jon, S. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J. Control. Release 2011, 155, 435–441.
153. MacAdam, A.B.; Shafi, Z.B.; James, S.L.; Marriott, C.; Martin, G.P. Preparation of hydrophobic and hydrophilic albumin microspheres and determination of surface carboxylic acid and amino residues. Int. J. Pharm. 1997, 151, 47–55.
154. Wang, G.; Uludag, H. Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. Expert Opin. Drug Deliv. 2008, 5, 499–515.
155. Xie, L.; Tong, W.; Yu, D.; Xu, J.; Li, J.; Gao, C. Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery. J. Mater. Chem. 2012, 22, 6053–6060.
156. Yang, L.; Meng, L.; Zhang, X.; Chen, Y.; Zhu, G.; Liu, H.; Xiong, X.; Sefah, K.; Tan, W. Engineering polymeric aptamers for selective cytotoxicity. J. Am. Chem. Soc. 2011, 133, 13380–13386.
157. Wu, C.; Han, D.; Chen, T.; Peng, L.; Zhu, G.; You, M.; Qiu, L.; Sefah, K.; Zhang, X.; Tan, W. Building a multifunctional aptamer-based DNA nanoassembly for targeted cancer therapy. J. Am. Chem. Soc. 2013, 135, 18644–18650.
158. Hu, R.; Zhang, X.; Zhao, Z.; Zhu, G.; Chen, T.; Fu, T.; Tan, W. DNA nanoflowers for multiplexed cellular imaging and traceable targeted drug delivery. Angew. Chem. Int. Ed. 2014, 53, 5821–5826.
159. Zhu, G.; Hu, R.; Zhao, Z.; Chen, Z.; Zhang, X.; Tan, W. Noncanonical self-assembly of multifunctional DNA nanoflowers for biomedical applications. J. Am. Chem. Soc. 2013, 135, 16438–16445.
160. Zhu, G.; Zheng, J.; Song, E.; Donovana, M.; Zhang, K.; Liu, C.; Tan, W. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc. Natl. Acad. Sci. USA 2013, 110, 7998–8003.
161. Zhou, J.; Li, H.; Li, S.; Zaia, J.; Rossi, J.J. Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy. Mol. Ther. 2008, 16, 1481–1489.
162. Kim, E.; Jung, Y.; Choi, H.; Yang, J.; Suh, J.-S.; Huh, Y.-M; Kim, K.; Haam, S. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 2010, 31, 4592–4599.
163. Herrmann, A.; Priceman, S.J.; Kujawski, M.; Xin, H.; Cherryholmes, G.A.; Zhang, W.; Zhang, C.; Lahtz, C.; Kowolik, C.; Forman, S.J. et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J. Clin. Investig. 2014, 124, 2977–2987.